Articles tagged with Drug Therapy
Researchers at the University of Sheffield have identified an antibody that can potentially become a new treatment for pulmonary arterial hypertension. Treatment with this specific antibody was found to reverse the process behind PAH development, showing promise for clinical development.
A new economic study by USC researchers suggests that breakthrough treatments for wet age-related macular degeneration (wAMD) offer significant patient benefits and societal value. The treatments generate $5.1 to $8.2 billion in patient benefits, translating to $0.9 to $3.0 billion in societal value over three years.
A study by Mount Sinai researchers found that more than half of patients taking ruxolitinib gained over 5% in body weight, associated with increased systolic blood pressure and liver enzymes. The study highlights the need for physicians to counsel patients about potential metabolic effects.
A study of over 24,000 Swedish adults found that those with a family history of schizophrenia and lower IQ are more likely to experience treatment-resistant schizophrenia. The condition is associated with higher risk for suicide and significant health costs.
Researchers at Penn Medicine have discovered that a higher dose of rituximab is more likely to put patients with pemphigus into complete remission compared to the standard treatment regimen. The study found that patients over 65 had a nearly 10-fold greater chance of achieving complete remission, while those with moderate to severe obe...
Researchers found that patients with cardiogenic shock developed malignant arrhythmias, and intense cooling may increase MA incidence. Risk factors included faster temperature decline and lower serum potassium levels during the cooling period.
Researchers identified therapy-induced mutations that cause drug resistance in children with acute lymphoblastic leukemia who relapse. Thiopurine treatment may prime patients for relapse, and precision medicine approaches, such as immunotherapies, are being explored.
Researchers at Temple University have discovered that an existing HIV drug can suppress Zika virus infection by targeting a common enzyme. The study opens the door to developing a broad-spectrum treatment strategy for multiple RNA virus infections using the same approach.
A study by the Eastern Cooperative Oncology Group found that lenalidomide delayed disease progression and improved overall survival in high-risk smoldering multiple myeloma patients. The treatment reduced serious adverse events, but it is unclear if it affects overall survival.
AcuraStem has secured a $3 million Phase II funding for its AS-1 Program, a lead small molecule program targeting amyotrophic lateral sclerosis (ALS). The award allows the company to accelerate the AS-1 program and expand its iNeuroRx technology platform.
Quinacrine repurposed with cisplatin synergizes to reduce cancer growth, increasing median time to tumor volume by 12 days; enhances apoptosis and inhibits autophagy in HNSCC cells.
The Wake Forest Institute for Regenerative Medicine has been awarded a five-year, $24 million grant from the US Department of Health and Human Services to advance its lung-on-a-chip technology. The funding will be used to model the effects of chlorine gas on human lungs and develop treatments for resulting injuries.
A study found that nearly a third of patients with severe asthma are taking harmful doses of oral steroids. Improving adherence to inhaled therapies and inhaler technique can help avoid this. However, only half of eligible patients receive biologic asthma drugs, which could reduce exposure to harmful oral steroids.
A doctor, who is also the father of a child with type 1 spinal muscular atrophy (SMA), offers a personal perspective on the benefits of the new treatment nusinersen. The medication has shown significant improvement in his son's condition, allowing him to regain motor skills and autonomy.
Researchers found anticholinergic drugs like glycopyrrolate significantly reduced drooling, but caused adverse effects such as behavioral changes and dehydration. The study suggests choosing a medication with fewer side effects for those with severe motor impairment.
The Lancet Respiratory Medicine published a series of papers on cystic fibrosis treatment, including new CFTR modulator drugs showing promise and improving patient outcomes. Additionally, a three-in-one inhaler therapy was found to improve lung function and reduce asthma attacks in patients with severe asthma.
A survey of elderly patients with type 2 diabetes found that many long-time patients downplay medical and social factors in favor of more aggressive treatment. The study's findings suggest that patients' perceptions of their care diverge from professional recommendations, highlighting the need for better physician-patient communications.
A novel initiative called the Stroke Preclinical Assessment Network (SPAN) is testing six potential new stroke therapies, including compressing the arm with a blood pressure-like cuff. This approach, known as remote ischemic conditioning, may reduce stroke size and improve patient recovery.
A unique partnership between an engineer and a scientist challenged prevailing wisdom about Toxoplasma gondii's behavior, revealing potential targets for treatment. The team's work showed that parasites are actively replicating with complex patterns, forcing a reconsideration of the parasite's life cycle.
A recent study analyzed deaths associated with ibrutinib and identified several cardiovascular toxicities, including supraventricular arrhythmias and heart failure. The study highlights the need to improve management of patients taking this drug, which has a higher death rate compared to chemotherapy.
The Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP) aims to accelerate the development of treatments for rare diseases by providing data and analytics. The platform, launched by C-Path and NORD, will facilitate collaboration among key stakeholders, including patients, industry, and regulatory agencies.
A large cohort study confirms that adding transarterial chemoembolization (TACE) to sorafenib improves survival rates in patients with advanced liver cancer, with median overall survival increasing by up to 26%. The treatment combination also shows similar tolerability compared to sorafenib alone.
Frostbite can be prevented by wearing proper clothing, avoiding wind-chill, and addressing pre-existing conditions that may affect circulation. Early treatment with thrombolytic therapies like iloprost can help prevent tissue loss and promote recovery.
A new study comparing heart attack care in Sweden and the UK found that patients in Sweden had lower mortality rates for both STEMI and NSTEMI forms of heart attacks. The results suggest improved outcomes due to increased use of invasive treatments and recommended medications in Sweden.
Scientists developed a novel nanotechnology-based approach that successfully delivered checkpoint inhibitors directly to brain tumors, triggering a local immune response and inducing tumor cell death. The treatment has shown promising results in laboratory mice, providing hope for longer survival rates for patients with glioblastoma
A new chip has been developed that can replicate the effects of osteoarthritis, allowing for the testing of pharmacological treatments. The chip uses mechanical stress to induce inflammation and degenerative processes, making it a more realistic model for disease development.
This special issue in the Journal of Pediatric Rehabilitation Medicine highlights the importance of multidisciplinary care in managing cerebral palsy. The articles cover various topics, including scoliosis care, goal setting, exercise programs and nutritional care, to improve outcomes for individuals with CP.
Researchers at Ohio State University have made significant breakthroughs in gene replacement therapy for Niemann-Pick type A disease, demonstrating its safety and therapeutic effects in nonhuman primates and mouse models. The treatment has shown a 'bystander effect', preventing motor and memory impairment and increasing survival rates.
A recent study published in Pain Medicine found that self-administered acupressure can improve symptoms of chronic low back pain. Researchers compared three groups: relaxing acupressure, stimulating acupressure, and usual care, with the acupressure groups experiencing pain and fatigue improvement after six weeks.
Researchers identify various disease mechanisms underlying progressive MS, highlighting the need for precise therapy approaches targeting different pathomechanisms. Financial obstacles, including patent expirations, also hinder the development of new drugs.
Severe malaria cases in the US are increasing, with limited access to IV treatment. Malaria expert Mark Travassos calls for improved access to intravenous quinidine gluconate, a critical medication for serious cases.
Researchers have identified a new therapeutic target for patients with Castleman disease who do not respond to the currently approved drug siltuximab. The PI3K/Akt/mTOR pathway, when inhibited, shows promise in sending patients into remission.
The Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP) aims to reduce barriers for rare disease treatment development. The platform will provide a centralized infrastructure to support accelerated therapy development, leveraging integrated data from various sources and advanced analytics expertise.
Conversion therapy practices cause significant harm, including depression, suicidal thoughts, and economic burdens. Physicians advocate for education reform to better identify patients who underwent or may be undergoing conversion therapy.
A new treatment could protect brain cells affected by Parkinson's disease, potentially slowing or stopping its progression. Dr Heather Mortiboys and her team will modify drug compounds that boost cell function in people living with Parkinson's.
A new study found that individuals with familial hypercholesterolemia (FH) or atherosclerotic heart disease (ASCVD) experienced more cardiovascular events when they couldn't get their prescribed LDL-cholesterol lowering medication. Those whose PCSK9 inhibitors were rejected by insurance had a 16% increased risk of a cardiovascular even...
A QUT study found that only 57.6% of pharmacies in Brisbane followed dispensing behavior compliant with therapeutic guidelines, while 31.3% oversold or over-treated medication. The study highlights the need for better guidance and training for pharmacists to ensure effective treatment outcomes.
GlycoNet has awarded $885,000 in grants to seven research projects across Canada focusing on improving health outcomes for conditions such as heart disease, infections, cancer, and diabetes. The projects aim to develop accessible solutions through glycomics research.
A study analyzing 216 early benefit assessments in Germany found that half of new drugs lack proven added benefits. The researchers call for mandatory comparisons between new and standard treatments to improve patient care.
Researchers argue that international drug development processes and policies are responsible for the lack of evidence supporting added benefits for most new drugs. Only 54 out of 216 assessed drugs showed considerable or major added benefits, with many more lacking clear evidence of benefit over standard care.
A new antibody treatment for high-frequency migraines has been found to be ineffective in reducing headache frequency among patients. Only six out of 28 patients reported a reduction of at least 25 percent in headache days, with none achieving a 50 percent reduction.
For high-risk patients, treatment continuation outweighs rare side effects; rapid bone loss occurs after denosumab discontinuation. Long-term studies showed no increased fracture risk with continued treatment.
Researchers at WVU have mapped the crystal structure of a protein called mitoNEET, which inhabits the outer membrane of mitochondria. This discovery could lead to disease-modifying treatments for Alzheimer's disease, stroke, and diabetes. The study uses advanced X-ray techniques to understand how molecules interact with the protein.
Researchers at Karolinska Institutet have developed a new method to divide patients with ulcerative colitis into two groups based on conserved gene expression across species. The study found that 87% of patients in one group responded poorly to treatment, while 60% in the other group showed improvement.
A recent study published in JAMA Internal Medicine examines the impact of disease definition, comorbidity burden, and prognosis on hip fracture probability among late-life women. The research found that women with osteoporosis and comorbidities have a high probability of hip fractures despite competing mortality risk.
A recent study by the University of Granada's Tissue Engineering Research Group has found that resident hospital doctors specialising in Family Medicine lack sufficient training on advanced therapies. The researchers also discovered a positive attitude among these doctors towards the use and application of such therapies.
A survey of psoriasis patients found that they often turn to complementary and alternative therapies, such as vitamins D and B12, when traditional medications fail. Despite limited evidence supporting these treatments, patients report therapeutic benefits from Dead Sea treatments.
A new study found that elderly patients with metastatic renal cell carcinoma who received targeted therapies experienced improved overall survival rates compared to those treated with older, more toxic treatments. The study analyzed data from over 1,100 Medicare patients and showed a three-month survival advantage with targeted therapies.
Researchers identified several potential therapeutic targets for Alport syndrome, including bardoxolone and anti-miRNA21. The disease is characterized by progressive kidney damage and proteinuria, and current treatments are primarily aimed at slowing disease progression rather than halting it.
Research published by the American Heart Association found that pre-treated patients with off-label selective vasodilator drugs are more likely to develop right-sided heart failure after LVAD implantation, increasing their risk of worse outcomes.
A randomized controlled trial found that telemedicine cognitive behavioral therapy for insomnia was equally effective to in-person delivery in improving sleep outcomes. Participants reported no differences in therapist alliance or satisfaction with treatment between the two groups.
A pilot study suggests that patients with chronic kidney disease who wear medical-alert accessories have a lower risk of developing kidney failure. However, there is no significant difference in rates of hospitalization or death between those who wear the accessories and those who do not.
A new Northwestern University study suggests that parents of depressed teenagers should also receive counseling to address their marital relationships and parent-child conflicts. The research found that while the teenager's depression was being treated, parental marriages and conflict remained stable, but worsened after treatment ended.
A new study published in Nature Digital Medicine found that smartphone-based relaxation technique RELAXaHEAD can reduce migraine headache days by four per month. The app's success rate increased from 51% to 29% after three months, suggesting its potential as a treatment option.
Research at North Carolina State University found that people with substance-use problems are less likely to report wanting effective therapies if they read a message describing addiction as a disease. In contrast, those who received a growth mindset message reported stronger intentions to seek counseling or cognitive-behavioral therapy.
Children with type 1 diabetes experience a 20% reduction in medication adherence during school holidays, weekends, and public holidays. This can have serious consequences for their health, increasing demand on healthcare systems and potentially leading to hospitalization and mortality.
The Children's Tumor Foundation has launched the NF2 Accelerator Initiative, a three-year research effort to bring active NF2 treatments to patients. The initiative focuses on expanding the clinical drug pipeline, improving drug selection through innovative testing models, and developing gene therapy options.
Researchers found that xenon gas treatment shortly after a head injury prevents early death and long-term cognitive impairment in mice. The treatment also protects brain tissue and reduces inflammation, which may lead to new treatments for people with TBI. This study provides promising results for future human trials.
Patients with severe eosinophilic asthma continued to experience fewer exacerbations and improved pulmonary function with long-term benralizumab treatment. The BORA study found that the risk of infection did not increase over time, and long-term use was well-tolerated.
A recent study published in the Journal of the American Dental Association found that patients who received comprehensive oral care as part of their substance use disorder treatment had a significant increase in completing their treatment programs. The results show that participants who underwent FLOSS (Facilitating a Lifetime of Oral ...